MolecularMD is expected to expand Icon's laboratory services by enabling it to better support precision medicine programs for drug-diagnostic codevelopment.
The draft guidelines have intrigued industry players interested in pursuing labeling that would allow their CDx to direct treatment for a class of drugs instead of one drug.
The firms said they will integrate their capabilities and competencies to offer solutions to global pharmaceutical customers.
The tests from Asuragen and MolecularMD are designed for use in chronic myeloid leukemia patients, including those receiving tyrosine kinase inhibitor therapy.
Agendia said this week that US Oncology has joined its FLEX breast cancer registry study.
The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.
The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.